Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17162601 | 0.98 | KDM4E (0.37) | ALDH1A1MAPTKDM4ECYP1A2CYP2D6 | |
| SCHEMBL29140392 | 0.84 | ALDH1A1 (0.37) | ALDH1A1MAPTKDM4ECYP1A2CYP2D6 | |
| SCHEMBL6706697 | 0.84 | ALDH1A1 (0.37) | ALDH1A1MAPTKDM4ECYP1A2CYP2D6 | |
| SCHEMBL25590375 | 0.83 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPK1 | |
| SCHEMBL7284553 | 0.82 | NAAA (0.39) | — | |
| SCHEMBL9438740 | 0.82 | ALDH1A1 (0.36) | ALDH1A1MAPTKDM4ECYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL29393853 | 0.82 | KDM4E (0.38) | ALDH1A1MAPTKDM4ECYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL28434875 | 0.82 | KDM4E (0.38) | ALDH1A1MAPTKDM4ECYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL7954813 | 0.82 | KDM4E (0.38) | ALDH1A1MAPTKDM4ECYP1A2CYP2D6 | |
| SCHEMBL7351046 | 0.81 | NAAA (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | THE UNIVERSITY OF CHICAGO (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2024-12-19 | — | — | US | disclosed |
| US-20240409556-A1 | BENZOPIPERAZINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. | 2024-12-12 | — | — | US | disclosed |
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2022-10-11 | — | — | US | disclosed |
| US-20220177422-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | THE UNIVERSITY OF CHICAGO (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220040207-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3946301-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | The University of Chicago (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3750910-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV Healthcare UK(No.4) Limited (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2020-11-19 | — | — | US | disclosed |
| WO-2020206118-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2020-10-08 | — | — | WO | disclosed |
| EP-0057536-A1 | Pharmaceutically active compounds | BEECHAM GROUP PLC (GB) | 1982-08-11 | — | — | EP | disclosed |
| US-4220465-A | PREEMERGENCE OR POSTEMERGENCE HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-09-02 | — | — | US | disclosed |
| US-4179276-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
| US-4117127-A | INHIBITION AND SUPPRESSION OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1978-09-26 | — | — | US | disclosed |
| US-4101653-A | ANTITHROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1978-07-18 | — | — | US | disclosed |
| US-4097472-A | INHIBITION AND SUPRESSION OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-06-27 | — | — | US | disclosed |
| US-4096255-A | ANTICOAGULANTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-06-20 | — | — | US | disclosed |
| US-4093712-A | ANTITHROMBOGENIC AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-06-06 | — | — | US | disclosed |
| US-4073913-A | INHIBITION AND SUPPRESSION OF THROMBIN | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-02-14 | — | — | US | disclosed |
| US-4066773-A | ANTITHROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040207-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | HIF1AN, RHOXF2, HIF1A | ALDH1A1 2857/4885MAPT 4394/4885KDM4E 2561/4885 |
| US-20220177422-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | MYLK, MFAP1, FIBP | ALDH1A1 3220/4885MAPT 4699/4885KDM4E 2386/4885 |
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885MAPT 4178/4885KDM4E 2728/4885 |
| US-20240409556-A1 | BENZOPIPERAZINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | YAP1, TEAD2, TEAD3 | ALDH1A1 2373/4885MAPT 3276/4885KDM4E 985/4885 |
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | MYLK, MFAP1, FIBP | ALDH1A1 3220/4885MAPT 4699/4885KDM4E 2386/4885 |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | HIF1AN, RHOXF2, HIF1A | ALDH1A1 2857/4885MAPT 4394/4885KDM4E 2561/4885 |
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885MAPT 4178/4885KDM4E 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.